[4] (d ( S - (+) -) l - ( - (-) -))
The global semaglutide market (Ozempic, Wegovy, Rybelsus and others) was worth about 2829 billion USD in 2024 alone .[16][17][18] Market analysts project it could reach around 9094 billion USD per year by 2035 in a basecase scenario.[15][18][16] Given these annual numbers, cumulative worldwide sales from launch (2017) to now easily run into many tens of billions of dollars , and over its full commercial life semaglutide is on track to become one of the most lucrative drug franchises in history.[17][18][15] Key point: Semaglutide is not just a blockbuster
With France joining the UK, Switzerland, Japan, and the United States in advancing insurance reimbursement for obesity drugs within public healthcare programs, obesity is increasingly being recognized not as a matter of individual lifestyle choices but as a chronic disease requiring state management
This combination speeds evaluation, reduces unnecessary trips, and provides a second opinion that can be taken to an in-person provider if further testing is necessary
And so doctors are increasingly prescribing the drug off-label, purely for its effect helping people lose weight
You can read more about our cancellation policy here
